Sun Pharma slips 1%; launches BromSite in USA

India Infoline News Service | Mumbai | November 29, 2016 17:43 IST

As the first branded ophthalmic product launched by Sun Ophthalmics business division, BromSite’s launch is a significant milestone for Sun Pharma in the USA, Abhay Gandhi said.

Sun Pharma
Sun Pharmaceuticals Industries Ltd ended at Rs 706.3, down by Rs 7.5 or 1.05% from its previous closing of Rs 713.8 on the BSE. Sun Pharma launched BromSite solution, marked for treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, in the US market.

The scrip opened at Rs 719.95 and touched a high and low of Rs 721.95 and Rs 703.4 respectively. A total of 4047300 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 171794.1 crore.

The BSE group 'A' stock of face value Rs 1 touched a 52 week high of Rs 898 on 23-Feb-2016 and a 52 week low of Rs 572.4 on 09-Nov-2016. Last one week high and low of the scrip stood at Rs 719.9 and Rs 681 respectively.

The promoters holding in the company stood at 54.97 % while Institutions and Non-Institutions held 33.34 % and 11.68 % respectively.

The stock traded below its 200 DMA.

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.